The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics.
about
Epigenetic regulators and their impact on therapy in acute myeloid leukemiaRevisiting the case for genetically engineered mouse models in human myelodysplastic syndrome researchEpigenetics in Cancer: A Hematological PerspectiveThe forkhead transcription factor FOXK2 acts as a chromatin targeting factor for the BAP1-containing histone deubiquitinase complexThe NF1 somatic mutational landscape in sporadic human cancers.Deep sequencing reveals stepwise mutation acquisition in paroxysmal nocturnal hemoglobinuria.O-GlcNAc signaling in cancer metabolism and epigeneticsMutations of epigenetic regulatory genes are common in thymic carcinomasASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group.Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemiaRole of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.Acquired ASXL1 mutations are common in patients with inherited GATA2 mutations and correlate with myeloid transformation.An evolutionary perspective on chronic myelomonocytic leukemia.Epigenetics of myelodysplastic syndromes.Integrating genetics and epigenetics in myelodysplastic syndromes: advances in pathogenesis and disease evolution.DUBs, the regulation of cell identity and disease.Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?ASXL1 mutation correction by CRISPR/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts.Maintaining cell identity: PRC2-mediated regulation of transcription and cancer.MBD5 and MBD6 interact with the human PR-DUB complex through their methyl-CpG-binding domain.ASXL gain-of-function truncation mutants: defective and dysregulated forms of a natural ribosomal frameshifting product?Leukemic transformation driven by an ASXL1 mutation after a JAK2V617F-positive primary myelofibrosis: clonal evolution and hierarchy revealed by next-generation sequencing.Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile.A bidentate Polycomb Repressive-Deubiquitinase complex is required for efficient activity on nucleosomes
P2860
Q26765402-8CE36303-D211-496E-ADEF-00AE207A59BAQ26859843-E7EC992F-96DB-4979-88C0-EEFAC686B534Q28077082-7A19A05D-4A31-4F9B-993F-6221B2733D76Q33698585-1AF5C08F-4DC4-4A5B-B910-C0D8CE307104Q33823452-7229DA26-341E-49EF-A268-ACA341CF220CQ34311583-5FB86BAE-3554-4EB1-9625-A7D80FEBD44CQ34401725-D3479F64-7A2F-438E-8251-E0020EFE47C8Q34648225-BC46A487-8C15-4539-985D-69A1D4EE8EA5Q35146279-37F8DF4C-F723-4A3D-8611-B6C89AA5BBA8Q35217865-97E61891-B105-4023-B7CE-D8AEDCFE591AQ35781605-C8A5812A-13B5-488B-B9D1-BF1423FE3DCDQ37552020-C1F55AA7-CABE-4FDC-904E-D7AB4D8FD10FQ38096235-FACBA97D-613F-440E-9455-9535E3EDF4A6Q38163846-83CB06B8-25CF-4EAE-87DC-5256F2AA70E4Q38218055-51782EA3-E898-49E4-B182-02181C3772CBQ38336126-01BFF852-1F16-4655-B5AE-FE66ACBC666BQ38664735-DBEF0AEB-29D0-4FD9-A280-F21151263FCBQ38815386-BD281C67-9ED9-4229-8FCD-9641D7966F82Q38961785-630A0E96-21CE-4B83-8DD3-D3A35C6B629BQ42648708-F316EB58-8928-4A29-9BBA-0D86888DEC23Q42689905-B3C9BA51-CDA4-436B-90D9-D21CCDD30840Q42854495-77EE4DCE-EAB3-499D-AC9B-3393F4BC7BB9Q55379234-EB3F0467-F732-469D-B4B0-48F17BFE2C28Q58695813-32756ECE-7FF5-49EC-A1D4-EBB149F8E59F
P2860
The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics.
@en
type
label
The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics.
@en
prefLabel
The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics.
@en
P2860
P356
P1433
P1476
The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics.
@en
P2093
P2860
P2888
P356
10.1038/LEU.2012.288
P577
2012-10-09T00:00:00Z
P5875
P6179
1011630840